Amino acid derivative
L-Carnitine
The Carnitor injection label gives a mean apparent terminal elimination half life of 17.4 hours for levocarnitine after a single intravenous dose; the app lists 15 hours.1
L-Carnitine after one dose: 50% at ~15 h, 25% at 30 h, 12.5% at 45 h.
Drawn from the half-life in the app's model, ~15 h. The model's figures
- Compound
- L-Carnitine
- Symbol
- LC
- Family
- Supplements
- Parts
- 14
- References
- 17
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
The app lists L-carnitine under the synonyms carnitine, ALCAR, acetyl-L-carnitine, LCLT and levocarnitine, and the Carnitor label calls levocarnitine "a naturally occurring substance required in mammalian energy metabolism".1 The app's notes describe an amino-acid derivative with three main forms (plain L-carnitine, acetyl-L-carnitine for cognition and the nervous system, and L-carnitine L-tartrate for exercise recovery) and give low oral bioavailability as the rationale for injectable use. The Carnitor injection label is headed "For Intravenous Use Only", and its two listed indications are an inborn error of metabolism that results in secondary carnitine deficiency and carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.1 The Carnitor tablet and oral solution label is headed "For oral use only. Not for parenteral use." and lists primary systemic carnitine deficiency and, in addition, an inborn error of metabolism that results in a secondary carnitine deficiency.2 The app grades the evidence as strong, which is the app's grade and not a conclusion of the sources.
How it works
Sources in this part
The injection label describes levocarnitine as "a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane".1 It states that levocarnitine "has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production", and that fatty acids are used as an energy substrate in all tissues except the brain.1 The label adds that the literature reports carnitine "can promote the excretion of excess organic or fatty acids in patients with defects in fatty acid metabolism".1 For patients with end stage renal disease on maintenance hemodialysis, it attributes possible low plasma carnitine to "reduced intake of meat and dairy products, reduced renal synthesis and dialytic losses".1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~15 h
- Bioavailability
- 15%
- Typical dose
- 500–2000 mg/day
- Route
- Oral / IM
- Time to peak
- ~3 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~15 h | Mean apparent terminal elimination half life of 17.4 hours (mean distribution half life 0.585 hours) after a slow 3 minute intravenous bolus of 20 mg/kg, using plasma concentrations uncorrected for endogenous levocarnitine, on the Carnitor labels; elimination half-life of 6.5 hours after 2 g and 3.9 hours after 6 g in a study of single intravenous and oral doses in 6 healthy subjects on a low carnitine diet, with the route of the half-life not named in the report1,2,3 |
| Bioavailability | 15% | Absolute oral bioavailability, calculated after correction for circulating endogenous levocarnitine, of 15.1 ± 5.3% for tablets and 15.9 ± 4.9% for oral solution on the Carnitor label; 16% for a 2 g oral dose and 5% for a 6 g oral dose in the 1988 study2,3 |
| Time to peak | ~3 h | Maximum plasma concentration of about 80 µmol/L with time to maximum plasma concentration at 3.3 hours after 4 days of twice-daily dosing in 15 healthy adult men; maximum serum concentration of a radiolabelled dose between 2.0 and 4.5 hours in five men2 |
| Model | One-compartment | Plasma profiles after an intravenous bolus "were described by a two-compartment model" on the label2 |
| Route | Oral and IM | Injection label: intravenous use only; tablet and solution label: oral use only, not for parenteral use1,2 |
| Protein binding | Not set in the app | Not bound to plasma protein or albumin at any concentration tested2 |
| Clearance and excretion | Not set in the app | Total body clearance a mean of 4.00 L/h; about 76% of an intravenous dose excreted in urine over 0 to 24 hours; about 9% of an oral dose excreted in urine over a 12 hour dosing interval at steady state2 |
Harper and colleagues (European Journal of Clinical Pharmacology, 1988, Danderyd Hospital, Sweden; 6 healthy subjects; publication type "Research Support, Non-U.S. Gov't") found dose-related elimination and suggested that "mucosal absorption of carnitine is already saturated at the 2-g dose".3
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: every 12 hours (steady-state study dosing on the label)2.
An illustration from a pharmacokinetic model using a half-life of 15 hours. It is not a measured level or a suggested dose.
Human studies
The human evidence below is mostly pooled analyses of randomized trials, plus tracer studies of how gut bacteria handle ingested carnitine; several of the pooled results carry high statistical heterogeneity, while others are lower (waist circumference I2 = 0.0% in the umbrella analysis, diastolic blood pressure I2 = 43.4%).5,6,8
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Pooyandjoo and colleagues, Obesity Reviews 20164 | Systematic review and meta-analysis of randomized controlled trials, random-effects model4 | 9 studies, total n = 911 adults4 | Duration of consumption examined by meta-regression4 | Weight MD -1.33 kg (95% CI -2.09 to -0.57) and BMI MD -0.47 kg/m2 (-0.88 to -0.05) against control; the weight loss decreased over time (p = 0.002)4 |
| Hamedi-Kalajahi and colleagues, International Journal for Vitamin and Nutrition Research 20255 | Umbrella meta-analysis of eight meta-analyses of placebo-controlled and controlled trials5 | 16,352 participants5 | 150 to 4000 mg/day; 8 to 30 weeks5 | Weight ES -1.11 (95% CI -1.90 to -0.33; I2 = 90.6%), BMI ES -0.33 (-0.61 to -0.04; I2 = 89.8%), waist circumference ES -1.34 (-1.83 to -0.85)5 |
| Zamani and colleagues, Frontiers in Nutrition 20226 | Systematic review and dose-response meta-analysis of 41 randomized trials6 | n = 2900 adults taking oral L-carnitine for at least seven days6 | Subgroups by duration and by dose below and at or above 2 g/day6 | Fasting glucose WMD -3.22 mg/dl (95% CI -5.21 to -1.23; I2 = 88.6%), HbA1c -0.27% (-0.47 to -0.07; I2 = 90.1%), HOMA-IR -0.73 (-1.21 to -0.25; I2 = 98.2%)6 |
| Mirrafiei and colleagues, Clinical Therapeutics 20247 | Dose-response meta-analysis of 21 randomized trials, GRADE-rated7 | 2041 adults with type 2 diabetes7 | Effects per 1 g/d of L-carnitine; linear reductions modelled up to 4 g/d7 | Per 1 g/d: HbA1c MD -0.16% (95% CI -0.32 to -0.01; I2 = 94%; GRADE moderate), BMI MD -0.37 kg/m2 (GRADE low), LDL cholesterol MD -0.11 mmol/L (GRADE high)7 |
| Anaraki and colleagues, Clinical Therapeutics 20248 | Meta-analysis of 22 randomized trials (24 effect sizes) of oral supplements8 | n = 1412 adults8 | Oral L-carnitine; dose-response and duration analyses8 | Systolic WMD -1.22 mm Hg (95% CI -3.79 to 1.35; P = 0.352), diastolic -0.50 mm Hg (-1.49 to 0.48; P = 0.318); diastolic -1.59 mm Hg (-3.11 to -0.06) in the baseline BMI above 30 kg/m2 subgroup8 |
| Liu and colleagues, Systematic Reviews 20239 | Meta-analysis of 8 randomized trials in non-alcoholic fatty liver disease, GRADE-rated9 | Adults and younger participants with NAFLD; 3 trials (192 patients) reported adverse events9 | Follow-up 12 or 24 weeks9 | ALT MD -26.38 (95% CI -45.46 to -7.30), low certainty, with no difference in younger participants (MD 0.4, 95% CI -1.32 to 2.12) and MD -31.7 (-47.61 to -15.79) in adults; HDL cholesterol MD 1.14 and triglycerides MD -6.92 (95% CI -13.82 to -0.03), moderate certainty; BMI MD 0.00 (-0.23 to 0.24) and weight MD -0.20 (-0.50 to 0.09), no difference at moderate certainty; adverse events RR 0.72 (0.47 to 1.08); the authors list as weaknesses that the trial and sample numbers are still relatively small and that two trials used a carnitine-orotate complex9 |
| Zhu and colleagues, International Urology and Nephrology 202110 | Meta-analysis of 18 randomized trials10 | 1090 people receiving hemodialysis10 | Effects independent of duration and route in subgroups10 | Erythropoietin responsiveness index MD -2.72 (95% CI -3.20 to -2.24); hemoglobin MD 0.18 (-0.20 to 0.55; P = 0.35)10 |
| Meng and colleagues, European Journal of Medical Research 202411 | Meta-analysis of 4 randomized trials against placebo11 | 356 critically ill patients with sepsis11 | Doses from 3 g/d for 7 days to 18 g/12 h across the trials11 | 28-day mortality RR 0.65 (95% CI 0.33 to 1.28; I2 = 70%; P = 0.21); 12-month mortality RR 0.72 (0.47 to 1.11)11 |
| Veronese and colleagues, Psychosomatic Medicine 2018, acetyl-L-carnitine12 | Systematic review and meta-analysis of 12 randomized trials of acetyl-L-carnitine alone or with antidepressants12 | 791 participants, mean age 54 years, 65% female12 | Searched from inception to 30 December 201612 | Depressive symptoms SMD -1.10 (95% CI -1.65 to -0.56; I = 86%) against placebo or no intervention in 9 trials; SMD 0.06 (-0.22 to 0.34) against antidepressants in 3 trials12 |
| Koeth and colleagues, Journal of Clinical Investigation 201913 | Stable-isotope tracer study with oral antibiotics, chronic supplementation and fecal culture (NCT01731236)13 | Omnivores (n = 40) and vegans/vegetarians (n = 32) for fasting levels13 | Chronic (2 months or more) l-carnitine supplementation in part of the study13 | d3-TMAO generation after oral d3-l-carnitine more than 20-fold higher in omnivores (P = 0.001)13 |
| Koeth and colleagues, Nature Medicine 201314 | Mouse experiments plus human carnitine challenge and a cardiac-evaluation cohort14 | Vegans/vegetarians (n=23), omnivores (n=51) and 2,595 people undergoing cardiac evaluation14 | Oral d3-carnitine challenge; antibiotics for a week in volunteers14 | Omnivores produced more TMAO than vegans or vegetarians; plasma carnitine predicted cardiovascular events only with concurrently high TMAO14 |
Sources in this part
Deeper analysis: glycemic markers meta-analysis (Zamani and colleagues, 2022)
Zamani and colleagues (Frontiers in Nutrition, 2022) searched PubMed, Scopus, Web of Science and the Cochrane databases in October 2022 for studies of oral L-carnitine taken for at least seven days in adults.6 Their pooled result across 41 trials in 2900 participants was a fasting glucose difference of -3.22 mg/dl, an HbA1c difference of -0.27% and a HOMA-IR difference of -0.73, each with I2 of 88.6% or higher.6 Serum insulin was not changed in the overall analysis (I2 = 96.5%), and the authors rate the evidence as low for fasting glucose, insulin and HOMA-IR and moderate for HbA1c.6 The authors name their own limitation: "most of the included articles showed high bias and heterogeneity which makes it difficult to reach a definitive conclusion about the effects of carnitine".6 They declare "the absence of any commercial or financial relationships that could be construed as a potential conflict of interest".6
Deeper analysis: blood pressure meta-analysis (Anaraki and colleagues, 2024)
Anaraki and colleagues (Clinical Therapeutics, 2024) searched four databases up to October 2022 for randomized trials in adults given oral L-carnitine.8 Across 22 trials (n = 1412) there was no significant effect on systolic pressure (I2 = 85.0%) or diastolic pressure (I2 = 43.4%).8 A subgroup analysis reported a diastolic reduction of 1.59 mm Hg (95% CI -3.11 to -0.06; P = 0.041) in participants with baseline BMI above 30 kg/m2, while the authors state that supplementation "had no lowering effect on SBP in any subgroup".8 The meta-analysis also reports a significant nonlinear relationship between the duration of the intervention and changes in systolic pressure (coefficients = -6.83, P = 0.045).8 The authors state that they "have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper".8
Deeper analysis: sepsis mortality meta-analysis (Meng and colleagues, 2024)
Meng and colleagues (European Journal of Medical Research, 2024) pooled four randomized trials of L-carnitine against placebo in 356 critically ill patients with sepsis, registered with INPLASY (INPLASY202460086).11 The trials in the review's table used L-carnitine at 12 g/12 h (Puskarich 2014, n = 31, and Evans 2019, n = 21), 6, 12 or 18 g/12 h (Jones 2018, n = 244) and 3 g/d for 7 days (Keshani 2024, n = 60).11 L-carnitine "was not associated with 28-day mortality" (RR 0.65; 95% CI 0.33 to 1.28; I2 = 70%; P = 0.21), and there was "no significant effect on 12-month mortality" (RR 0.72; 95% CI 0.47 to 1.11; I2 = 0%; P = 0.14).11 The authors list their limitations: "diverse doses and administration timings, different degrees of sepsis severity, and various comorbidities among patients could augment the uncertainty of the study conclusions", and "the current number of randomized controlled trials is relatively scarce, and some trials have relatively small sample sizes".11 The authors declare no competing interests.11
Deeper analysis: type 2 diabetes and acetyl-L-carnitine meta-analyses
Mirrafiei and colleagues (Clinical Therapeutics, 2024) write that "due to high statistical heterogeneity" their type 2 diabetes results call for very cautious interpretation, and they declare no known competing financial interests.7 Veronese and colleagues (Psychosomatic Medicine, 2018) pooled nine trials of acetyl-L-carnitine (231 treated, 216 on placebo and 20 with no intervention), list a Department of Health grant (ICA-CL-2017-03-001), and conclude that "Future large scale trials are required to confirm/refute these findings".12
Deeper analysis: hemodialysis meta-analyses (Zhu 2021, Chen 2014)
Two meta-analyses of people on maintenance hemodialysis reach different results on anemia outcomes.10,15 Zhu and colleagues (18 trials, 1090 participants) report an erythropoiesis-stimulating agent dose MD of -1.70 (95% CI -2.04 to -1.36), whereas Chen and colleagues (49 trials, 1734 participants) report a required erythropoietin dose MD of -0.76 KU/wk (95% CI -1.75 to 0.23).10,15 Zhu and colleagues write that "the relationship between L-carnitine treatment and long-term outcomes is still unclear", and their record lists grants from regional science and health bodies in Guangxi and Hengyang, China.10 Chen and colleagues write that the "relevance of decrease in CRP with hard endpoints such as all-cause mortality and cardiovascular complications still remains to be clarified", and their record lists the publication type "Research Support, Non-U.S. Gov't".15
Deeper analysis: gut microbiota and TMAO studies (Koeth and colleagues, 2013 and 2019)
Koeth and colleagues (Cleveland Clinic and collaborators, Nature Medicine, 2013) report that in mice, dietary L-carnitine supplementation altered cecal microbial composition, enhanced synthesis of TMA and TMAO and increased atherosclerosis, which did not occur if the intestinal microbiota was concurrently suppressed.14 That mouse result is not a result in people; the human parts of the paper are a carnitine challenge in volunteers and a cohort of 2,595 people undergoing cardiac evaluation.14 In the cohort, elevated carnitine (4th quartile) independently predicted major adverse cardiac events, but "the significant relationship between carnitine and MACE risk was completely attenuated" after further adjustment for TMAO and comorbidities.14 The authors conclude that the results are "consistent with TMAO, and not the dietary precursor carnitine, serving as the primary driver of the association with cardiovascular risks".14 The 2013 paper reports grants from the National Institutes of Health and the Leducq Foundation, and its disclosure states that Dr. Hazen "has been paid as a consultant or speaker" by companies including Cleveland Heart Lab, Esperion, Merck and Pfizer, has received research funds from Abbott, Cleveland Heart Lab, Esperion and Liposciences, has the right to receive royalty payments from Abbott Laboratories, Cleveland Heart Lab, Frantz Biomarkers, Liposciences and Siemens, and is named as a co-inventor on patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics.14 Koeth and colleagues (Journal of Clinical Investigation, 2019) followed with tracer studies in which volunteers ingested deuterium-labeled L-carnitine, and they report "a striking increase in d3-TMAO generation" in omnivores over vegans/vegetarians (more than 20-fold; P = 0.001), with fasting plasma L-carnitine similar between the groups.13 Their stated limitations include that antibiotics "can also have direct effects on the host", that hepatic tissue was not available, and that "the studies used relatively small numbers of individuals", which they say makes them "cautious about the generalizability of these studies to greater populations".13 The 2019 funding was from "NIH and Office of Dietary Supplements grants HL103866, HL126827, and DK106000, and the Leducq Foundation".13 Its conflict statement lists five authors as Procter & Gamble employees named as co-inventors on patents relevant to the work, states that three authors (ZW, BSL and SLH) are co-inventors on Cleveland Clinic patents with the right to receive royalty payment from Cleveland HeartLab, Quest Diagnostics and Procter & Gamble, and states that Hazen has been paid as a consultant by Procter & Gamble and has received research funds from Procter & Gamble and Roche.13 The registry entry for the associated CARNIVAL study (NCT01731236) names Stanley L Hazen, MD, PhD, of The Cleveland Clinic as the responsible investigator, and its overall status is active, not recruiting.16
Doses reported in studies and on labels
| Source | Dose, route and length as reported | Setting |
|---|---|---|
| Carnitor tablet label, adults2 | 990 mg two or three times a day using 330 mg tablets, depending on clinical response; oral2 | Primary systemic carnitine deficiency or secondary deficiency from an inborn error of metabolism2 |
| Carnitor tablet label, infants and children2 | 50 to 100 mg/kg/day in divided doses, with a maximum of 3 g/day; the label adds that the exact dosage depends on clinical response2 | Same labelled conditions2 |
| Carnitor injection label, metabolic disorders1 | 50 mg/kg as a slow 2-3 minute bolus injection or by infusion, intravenous; the highest dose administered has been 300 mg/kg1 | Inborn error of metabolism with secondary carnitine deficiency1 |
| Carnitor injection label, hemodialysis1 | Starting dose of 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session1 | End stage renal disease on hemodialysis1 |
| Type 2 diabetes meta-analysis 20247 | Effects per 1 g/d; BMI effect U-shaped with the largest reduction at 2 g/d; linear reductions in triglycerides, total cholesterol and fasting glucose up to 4 g/d7 | 21 trials, 2041 adults with type 2 diabetes7 |
| Sepsis meta-analysis 202411 | 12 g/12 h; 6, 12 or 18 g/12 h; 3 g/d for 7 days across the four trials11 | 356 critically ill patients with sepsis11 |
Side effects reported
Sources in this part
The injection label reports "Transient nausea and vomiting", with body odor, nausea and gastritis less often, and says an incidence "is difficult to estimate due to the confounding effects of the underlying pathology".1 It also lists adverse events at 5% or more regardless of causality from two double-blind, placebo-controlled trials in patients on chronic hemodialysis.1 The tablet label reports "Various mild gastrointestinal complaints" during long-term oral administration, including transient nausea and vomiting, abdominal cramps and diarrhea, and notes that its reports came "from a population of uncertain size" so frequency and causality cannot always be established.2 Both labels report seizures "in patients with or without pre-existing seizure activity" receiving oral or intravenous levocarnitine, and an increase in seizure frequency and/or severity in patients with pre-existing seizure activity.2,1 The injection label reports serious hypersensitivity reactions, including anaphylaxis, laryngeal edema and bronchospasm, "mostly in patients with end stage renal disease who are undergoing dialysis", and the tablet label lists rash, urticaria and facial edema with oral use.1,2 The labels report INR increases with warfarin, and state that chronic high-dose oral levocarnitine in patients with severely compromised renal function or on dialysis may result in accumulation of the "potentially toxic metabolites" TMA and TMAO.1 On overdosage, the tablet label states "There have been no reports of toxicity from levocarnitine overdosage" and that large doses "may cause diarrhea".2 In the acetyl-L-carnitine meta-analysis, the incidence of adverse effects "was significantly lower in the ALC group than in the antidepressant group" in the three trials that compared the two.12
Bloodwork and markers
The app lists no health markers to monitor for L-carnitine. The injection label defines carnitine deficiency biochemically as "abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term".1 In a 9-week study of 12 patients on hemodialysis for at least 6 months who received 20 mg/kg three times per week after dialysis, mean plasma levocarnitine was approximately 20 µmol/L pre-dialysis and 6 µmol/L post-dialysis before treatment, and after one week of treatment all patients had trough concentrations between 54 and 180 µmol/L against a stated normal of 40-50 µmol/L.1 The label's warfarin entry reports INR increases, and the meta-analyses above report fasting glucose, HbA1c, blood pressure, liver enzymes, lipids, C-reactive protein and the erythropoietin responsiveness index as outcomes.1,6,9,15
Regulatory and anti-doping status
The Carnitor injection label is for intravenous use only, and the tablet and oral solution label is for oral use only and not for parenteral use.1,2 The 2026 WADA Prohibited List states that it comes into effect on 1 January 2026, and a search of its saved text for "carnitine" returned no match.17 Method M2.2 of the same list prohibits "Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour" period, except those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.17 A DailyMed search for levocarnitine returned 18 labels, among them the Carnitor products and generic levocarnitine injections, tablets and solutions.
Storage and handling
Sources in this part
The Carnitor injection label states "Store vials at controlled room temperature (25°C)" and that the unused portion of a vial is discarded "as the formulation does not contain a preservative".1 The tablet label states "Store in original packaging: content hygroscopic" and gives 20°C to 25°C (68°F to 77°F); for the oral solutions it adds "Avoid excessive heat and protect from freezing".2
What is not known
Sources in this part
The injection label states that the effects of supplemental carnitine on the signs and symptoms of carnitine deficiency and on clinical outcomes in dialysis patients "have not been determined".1 It also states that "The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency".1 The label states that there are "no adequate and well controlled studies in pregnant women" and that supplementation in nursing mothers "has not been specifically studied".1 The Carnitor injection label describes intravenous use only, and a DailyMed search for levocarnitine with the word intramuscular returned 0 labels.1 A search of ClinicalTrials.gov for "carnitine intramuscular" returned one study, a withdrawn phase 4 trial of L-carnitine in respiratory distress syndrome (NCT03630367), and the titles of the 20 PubMed records displayed for "intramuscular injection L-carnitine" did not include an intramuscular levocarnitine pharmacokinetic study. The label half-life of 17.4 hours is for an intravenous dose, and the app's 15 hours is not tied to a route in the sources read.1
Frequently asked questions
What is the half-life of L-carnitine?
The Carnitor labels give a mean apparent terminal elimination half life of 17.4 hours after a single intravenous dose, and the app lists 15 hours.1,2 A 1988 study of single intravenous and oral doses in 6 healthy subjects reported elimination half-lives of 6.5 hours after 2 g and 3.9 hours after 6 g, without naming the route for the half-lives.3
How well is oral L-carnitine absorbed?
How long does L-carnitine take to reach its peak level?
The Carnitor label reports a time to maximum plasma concentration of 3.3 hours after 4 days of twice-daily oral dosing in 15 healthy men, and the app lists about 3 hours.2
Is L-carnitine banned by WADA?
A search of the saved text of the WADA 2026 Prohibited List for "carnitine" returned no match.17 The list's method M2.2 prohibits intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period, except those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.17
Does L-carnitine lower blood pressure in trials?
A 2024 meta-analysis of 22 randomized trials (n = 1412) of oral L-carnitine reported no significant effect on systolic pressure (WMD -1.22 mm Hg, 95% CI -3.79 to 1.35) or diastolic pressure (WMD -0.50 mm Hg, 95% CI -1.49 to 0.48).8 In the subgroup with baseline BMI above 30 kg/m2, diastolic pressure fell by 1.59 mm Hg (95% CI -3.11 to -0.06).8
Does L-carnitine reduce mortality in sepsis?
A 2024 meta-analysis of four randomized trials (356 patients) reported that L-carnitine was not associated with 28-day mortality (RR 0.65, 95% CI 0.33 to 1.28; I2 = 70%).11 The same analysis reported no significant effect on 12-month mortality (RR 0.72, 95% CI 0.47 to 1.11), and the authors note that the number of randomized trials is relatively scarce and some have relatively small sample sizes.11
Does L-carnitine raise TMAO?
A tracer study reported a striking increase in d3-TMAO generation in omnivores over vegans/vegetarians after oral d3-l-carnitine, and a 2013 paper found formation of TMAO from carnitine in volunteers was suppressed after a week of antibiotics.13,14 The 2019 authors conclude that in humans dietary l-carnitine is converted into TMAO via two sequential gut microbiota-dependent transformations, and state that the studies used relatively small numbers of individuals.13
Has intramuscular L-carnitine been studied?
The Carnitor injection label describes intravenous use only, and a DailyMed search for levocarnitine with the word intramuscular returned 0 labels.1
Guides, tools and comparisons
References
- Leadiant Biosciences. Carnitor (levocarnitine) injection, for intravenous use only. US prescribing information, DailyMed record version 19, 22 November 2023. DailyMed injection label
- Leadiant Biosciences. Carnitor (levocarnitine) tablets, for oral use only. US prescribing information, DailyMed record version 21, 14 November 2024. DailyMed tablet label
- Harper P, Elwin CE, Cederblad G. Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. Eur J Clin Pharmacol 1988;35(5):555-62. PMID 3234464
- Pooyandjoo M, et al. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2016;17(10):970-6. PMID 27335245
- Hamedi-Kalajahi F, et al. The Effect of the L-Carnitine Supplementation on Obesity Indices: An Umbrella Meta-Analysis. Int J Vitam Nutr Res 2025;95(2):40033. PMID 40298161
- Zamani M, et al. The effects of L-carnitine supplementation on glycemic markers in adults: A systematic review and dose-response meta-analysis. Front Nutr 2022. PMC9871499
- Mirrafiei A, et al. The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Systematic Review and Dose-response Meta-Analysis of Randomized Controlled Trials. Clin Ther 2024;46(5):404-410. PMID 38594107
- Anaraki SR, et al. The Effects of L-Carnitine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-response Meta-analysis. Clin Ther 2024;46(2):e73-e86. PMID 38101999
- Liu A, et al. Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis. Syst Rev 2023. PMC10148537
- Zhu Y, et al. Effect of L-carnitine supplementation on renal anemia in patients on hemodialysis: a meta-analysis. Int Urol Nephrol 2021;53(10):2149-2158. PMID 33713287
- Meng C, et al. The supplementation of l-carnitine in critically ill patients with sepsis: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res 2024. PMC11453008
- Veronese N, et al. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom Med 2018;80(2):154-159. PMID 29076953
- Koeth RA, et al. l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest 2019. PMID 30530985
- Koeth RA, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19(5):576-85. PMC3650111
- Chen Y, et al. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis. Am J Clin Nutr 2014;99(2):408-22. PMID 24368434
- The Cleveland Clinic. CARNIVAL Study (NCT01731236). ClinicalTrials.gov registry entry, status verified March 2026. NCT01731236
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list